132 related articles for article (PubMed ID: 38278875)
1. Repotrectinib effective in ROS1-fusion-positive NSCLC.
Sidaway P
Nat Rev Clin Oncol; 2024 Mar; 21(3):167. PubMed ID: 38278875
[No Abstract] [Full Text] [Related]
2. Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer.
Yun MR; Kim DH; Kim SY; Joo HS; Lee YW; Choi HM; Park CW; Heo SG; Kang HN; Lee SS; Schoenfeld AJ; Drilon A; Kang SG; Shim HS; Hong MH; Cui JJ; Kim HR; Cho BC
Clin Cancer Res; 2020 Jul; 26(13):3287-3295. PubMed ID: 32269053
[TBL] [Abstract][Full Text] [Related]
3. Repotrectinib: First Approval.
Dhillon S
Drugs; 2024 Feb; 84(2):239-246. PubMed ID: 38279972
[TBL] [Abstract][Full Text] [Related]
4. Repotrectinib in
Drilon A; Camidge DR; Lin JJ; Kim SW; Solomon BJ; Dziadziuszko R; Besse B; Goto K; de Langen AJ; Wolf J; Lee KH; Popat S; Springfeld C; Nagasaka M; Felip E; Yang N; Velcheti V; Lu S; Kao S; Dooms C; Krebs MG; Yao W; Beg MS; Hu X; Moro-Sibilot D; Cheema P; Stopatschinskaja S; Mehta M; Trone D; Graber A; Sims G; Yuan Y; Cho BC;
N Engl J Med; 2024 Jan; 390(2):118-131. PubMed ID: 38197815
[TBL] [Abstract][Full Text] [Related]
5. Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition.
Facchinetti F; Rossi G; Bria E; Soria JC; Besse B; Minari R; Friboulet L; Tiseo M
Cancer Treat Rev; 2017 Apr; 55():83-95. PubMed ID: 28342334
[TBL] [Abstract][Full Text] [Related]
6. Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer.
Zhang L; Jiang T; Li X; Wang Y; Zhao C; Zhao S; Xi L; Zhang S; Liu X; Jia Y; Yang H; Shi J; Su C; Ren S; Zhou C
Cancer; 2017 Aug; 123(15):2927-2935. PubMed ID: 28346673
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement.
Zhang L; Jiang T; Zhao C; Li W; Li X; Zhao S; Liu X; Jia Y; Yang H; Ren S; Zhou C
Oncotarget; 2016 Nov; 7(46):75145-75154. PubMed ID: 27738334
[TBL] [Abstract][Full Text] [Related]
8. Validating ROS1 rearrangements as a therapeutic target in non-small-cell lung cancer.
Solomon B
J Clin Oncol; 2015 Mar; 33(9):972-4. PubMed ID: 25667277
[No Abstract] [Full Text] [Related]
9. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
[TBL] [Abstract][Full Text] [Related]
10. An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer.
Dziadziuszko R; Le AT; Wrona A; Jassem J; Camidge DR; Varella-Garcia M; Aisner DL; Doebele RC
J Thorac Oncol; 2016 Aug; 11(8):1273-1281. PubMed ID: 27068398
[TBL] [Abstract][Full Text] [Related]
11. [Clinical significance of ROS1 rearrangements in non-small cell lung cancer].
Xu L; Zhao R; Dong Z; Zhu T
Zhongguo Fei Ai Za Zhi; 2013 Dec; 16(12):663-70. PubMed ID: 24345493
[TBL] [Abstract][Full Text] [Related]
12. ROS1 [corrected].
Pal P; Khan Z
J Clin Pathol; 2017 Dec; 70(12):1001-1009. PubMed ID: 28903995
[TBL] [Abstract][Full Text] [Related]
13. Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement.
Wu J; Lin Y; He X; Yang H; He P; Fu X; Li G; Gu X
BMC Cancer; 2016 Aug; 16():599. PubMed ID: 27488371
[TBL] [Abstract][Full Text] [Related]
14. Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.
Song A; Kim TM; Kim DW; Kim S; Keam B; Lee SH; Heo DS
Clin Cancer Res; 2015 May; 21(10):2379-87. PubMed ID: 25688157
[TBL] [Abstract][Full Text] [Related]
15. Lung cancer: alternative rearrangements--targeting ROS1 in NSCLC.
Killock D
Nat Rev Clin Oncol; 2014 Nov; 11(11):624. PubMed ID: 25311353
[No Abstract] [Full Text] [Related]
16. [Crizotinib for ROS1-rearranged non-small cell lung cancer patients].
Domblides C; Antoine M; Lavole A; Cadranel J; Wislez M
Bull Cancer; 2017 Apr; 104(4):303-310. PubMed ID: 28237354
[TBL] [Abstract][Full Text] [Related]
17. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
Kato Y; Ninomiya K; Ohashi K; Tomida S; Makimoto G; Watanabe H; Kudo K; Matsumoto S; Umemura S; Goto K; Ichihara E; Ninomiya T; Kubo T; Sato A; Hotta K; Tabata M; Toyooka S; Maeda Y; Kiura K
Cancer Sci; 2018 Oct; 109(10):3149-3158. PubMed ID: 30053332
[TBL] [Abstract][Full Text] [Related]
18. ROS1 rearrangements define a unique molecular class of lung cancers.
Bergethon K; Shaw AT; Ou SH; Katayama R; Lovly CM; McDonald NT; Massion PP; Siwak-Tapp C; Gonzalez A; Fang R; Mark EJ; Batten JM; Chen H; Wilner KD; Kwak EL; Clark JW; Carbone DP; Ji H; Engelman JA; Mino-Kenudson M; Pao W; Iafrate AJ
J Clin Oncol; 2012 Mar; 30(8):863-70. PubMed ID: 22215748
[TBL] [Abstract][Full Text] [Related]
19. Response to crizotinib observed in metastatic mediastinum lymph node from a non-small cell lung cancer patient harboring EZR-ROS1 fusion.
Li H; Pan Y; Wang R; Li Y; Sun Y; Chen H
J Cancer Res Clin Oncol; 2015 Jan; 141(1):185-7. PubMed ID: 25230898
[No Abstract] [Full Text] [Related]
20. [A new target in non-small cell lung cancer: ROS1 fusion gene].
Cai WJ; Su B
Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):1-4. PubMed ID: 23648291
[No Abstract] [Full Text] [Related]
[Next] [New Search]
